Similar companies
| Company | Business Outlook | |
|---|---|---|
 |
AmgenAMGN |
77 0% |
 |
Gilead SciencesGILD |
59 1.7% |
 |
Catalyst PharmaceuticalsCPRX |
100 0% |
 |
Inovio PharmaceuticalsINO |
23 0% |
 |
Anavex Life SciencesAVXL |
0 0% |
Month over Month
Employee view on business outlook (0 - 100)
| Nov 2024 | 46 | |
| Oct 2024 | 46 | |
| Sep 2024 | 46 | |
| Aug 2024 | 46 |
How do employees feel about the future at Crispr Therapeutics?
The Business Outlook at Crispr Therapeutics is negative, according to employees. The rating, which is an average compiled from the top review sites in the US, is below average at 46 out of 100. Additionally, this rating has been trending downward in comparison to the previous month.
Analyzing Business Outlook, how is Crispr Therapeutics performing compared to its industry peers?
Compared to its peers, Crispr Therapeutics ranks in the 46th percentile when it comes to Business Outlook.
How has the business outlook at Crispr Therapeutics changed over the last couple of months
There has been no meaningful change in the business outlook amongst employees at Crispr Therapeutics.
Why is it important to track the business outlook at Crispr Therapeutics?
Tracking a company's business outlook is important as a positive outlook can indicate future growth and profitability and attract new talent, while a negative outlook can discourage talent and imply demotivated employees. Additionally, data shows that companies with a high business outlook tend to perform better on the stock market compared to those with a lower business outlook.
Sign up and get more insights on the business outlook at Crispr Therapeutics.
